WO2024259428A3 - Estrogenic compounds and formulations for gestation-related complications - Google Patents

Estrogenic compounds and formulations for gestation-related complications Download PDF

Info

Publication number
WO2024259428A3
WO2024259428A3 PCT/US2024/034368 US2024034368W WO2024259428A3 WO 2024259428 A3 WO2024259428 A3 WO 2024259428A3 US 2024034368 W US2024034368 W US 2024034368W WO 2024259428 A3 WO2024259428 A3 WO 2024259428A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulations
gestation
related complications
estrogenic compounds
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/034368
Other languages
French (fr)
Other versions
WO2024259428A2 (en
Inventor
Fatima CHLEILAT
Michael P. Snyder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of WO2024259428A2 publication Critical patent/WO2024259428A2/en
Publication of WO2024259428A3 publication Critical patent/WO2024259428A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formulations, compounds, and methods to prolong gestation and for treatment of gestational complications are described. Treatments include administration of an estrogenic compound to mitigate uterine contractions.
PCT/US2024/034368 2023-06-16 2024-06-17 Estrogenic compounds and formulations for gestation-related complications Ceased WO2024259428A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363508763P 2023-06-16 2023-06-16
US63/508,763 2023-06-16

Publications (2)

Publication Number Publication Date
WO2024259428A2 WO2024259428A2 (en) 2024-12-19
WO2024259428A3 true WO2024259428A3 (en) 2025-03-13

Family

ID=93852720

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/034368 Ceased WO2024259428A2 (en) 2023-06-16 2024-06-17 Estrogenic compounds and formulations for gestation-related complications

Country Status (1)

Country Link
WO (1) WO2024259428A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119505212B (en) * 2025-01-17 2025-04-11 合肥工业大学 PBAT/bamboo powder compatible and crosslinking integrated auxiliary agent, preparation method and application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110118224A1 (en) * 2008-07-28 2011-05-19 Preglem Sa Use of steroid sulfatase inhibitors for the treatment of preterm labor
US20220339176A1 (en) * 2019-09-23 2022-10-27 The Board Of Trustees Of The Leland Stanford Junior University Methods of Treatments to Prolong Gestation and Complications of Menstruation or Gestation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110118224A1 (en) * 2008-07-28 2011-05-19 Preglem Sa Use of steroid sulfatase inhibitors for the treatment of preterm labor
US20220339176A1 (en) * 2019-09-23 2022-10-27 The Board Of Trustees Of The Leland Stanford Junior University Methods of Treatments to Prolong Gestation and Complications of Menstruation or Gestation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AKINWUNMI BABATUNDE, MING WAI-KIT: "Evaluating Vaginal Progesterone in Preventing Recurrent Preterm Birth: A Call to Action", JAMA NETWORK OPEN, JAMA NETWORK, vol. 5, no. 10, 3 October 2022 (2022-10-03), pages e2242247, XP093291468, ISSN: 2574-3805, DOI: 10.1001/jamanetworkopen.2022.42247 *
DATABASE PUBCHEM COMPOUND 25 March 2005 (2005-03-25), XP093291462, Database accession no. 3269 *
GARFIELD R E, SHI S-Q, SHI L.: "Use of progesterone and progestin analogs for inhibition of preterm birth and other uterine contractility disorders", FACTS, VIEWS AND VISION IN OBGYN, vol. 4, no. 4, 1 January 2012 (2012-01-01), pages 237 - 244, XP093291456 *
TAYLOR JESSICA, SHARP ANDREW, RANNARD STEVE P., ARROWSMITH SARAH, MCDONALD TOM O.: "Nanomedicine strategies to improve therapeutic agents for the prevention and treatment of preterm birth and future directions", NANOSCALE ADVANCES, ROYAL SOCIETY OF CHEMISTRY, vol. 5, no. 7, 28 March 2023 (2023-03-28), pages 1870 - 1889, XP093291460, ISSN: 2516-0230, DOI: 10.1039/D2NA00834C *

Also Published As

Publication number Publication date
WO2024259428A2 (en) 2024-12-19

Similar Documents

Publication Publication Date Title
CA2281755C (en) Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
JP2023503309A5 (en)
US6159944A (en) Method for treating painful conditions of the anal region and compositions therefor
JP2023503303A5 (en)
EP1063990B1 (en) Use of a biochanin-enriched extract for the treatment of estrogen-associated disorders
WO2024259428A3 (en) Estrogenic compounds and formulations for gestation-related complications
JP2003503313A5 (en)
KR20110045065A (en) Drugs for menstrual suppression, contraception and hormone replacement therapy and methods of administering the same
Smith Drug treatment of varicose veins, venous edema, and ulcers
CZ282840B6 (en) Pharmaceutical preparation and the use of ranitidine bismuth citrate and at least one antibiotic for preparing such pharmaceutical
MX2023005078A (en) New crystalline forms of a kras g12c inhibitor compound.
HUP0100012A2 (en) Use of macrolide compounds in the treatment of cancer and macular lesions
MX2025001642A (en) Topical treatment of skin cancer using oligopeptides
WO2019142124A4 (en) Pharmaceutical compositions for treatment of vitiligo
NZ521315A (en) Exemestane for first-line treatment of breast cancer
CA3013734C (en) Method and composition for treatment and prevention of broad spectrum virus ailments
US20180271786A1 (en) Enema for rectal application
CN105147703A (en) Application of obakurone to preparation of medicines or food for preventing and treating ulcerative colitis
WO2023183816A3 (en) Compositions and methods for promoting wound healing and minimizing scarring
EP1641470B1 (en) Vaginal compositions for treating pelvic tissue infections and traumas
CN104983728A (en) Application of acacetin in preparing of ulcerative colitis preventing medicine or food
PH12022553502A1 (en) Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine
Hellman Neomycin, a new antibiotic active against streptomycin-resistant bacteria, including tuberculosis organisms: Waksman, Selman A., and Lechevalier, Hubert A.: Science 109: 305, March 25, 1949
JP2023502251A (en) Method for inducing or promoting farnesoid X receptor (FXR)-mediated transcriptional response
CN105078960A (en) Application of genkwanin in preparing medicines or food for preventing and treating ulcerative colitis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24824354

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE